GLAXO - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.8
| Stock Code | GLAXO | Market Cap | 39,959 Cr. | Current Price | 2,360 ₹ | High / Low | 3,516 ₹ |
| Stock P/E | 40.2 | Book Value | 101 ₹ | Dividend Yield | 1.78 % | ROCE | 62.6 % |
| ROE | 46.4 % | Face Value | 10.0 ₹ | DMA 50 | 2,423 ₹ | DMA 200 | 2,551 ₹ |
| Chg in FII Hold | -0.01 % | Chg in DII Hold | -0.02 % | PAT Qtr | 277 Cr. | PAT Prev Qtr | 253 Cr. |
| RSI | 44.2 | MACD | -10.1 | Volume | 1,10,064 | Avg Vol 1Wk | 1,35,015 |
| Low price | 2,218 ₹ | High price | 3,516 ₹ | PEG Ratio | -2.03 | Debt to equity | 0.02 |
| 52w Index | 11.0 % | Qtr Profit Var | 21.3 % | EPS | 58.8 ₹ | Industry PE | 30.9 |
📊 Glaxo shows strong profitability with ROCE at 62.6% and ROE at 46.4%, reflecting excellent capital efficiency. The company maintains a low debt-to-equity ratio (0.02), ensuring financial stability. Dividend yield of 1.78% adds moderate income support. However, the P/E of 40.2 is high compared to the industry average of 30.9, and the negative PEG ratio (-2.03) signals weak growth prospects relative to valuation. Current price ₹2,360 is below both 50 DMA (₹2,423) and 200 DMA (₹2,551), indicating bearish momentum. RSI at 44.2 and MACD negative (-10.1) further suggest weakness. Quarterly PAT growth (+21.3%) is encouraging but valuations remain stretched.
💡 Ideal Entry Zone: ₹2,200 – ₹2,300 (near 52-week low support).
📈 Exit Strategy: Investors already holding may consider a medium-term horizon (2–3 years). Partial profit booking can be done near ₹3,200–₹3,400 resistance levels. Long-term holding should be cautious given high valuations and weak PEG ratio, despite strong ROE and ROCE.
Positive
- Exceptional ROCE (62.6%) and ROE (46.4%).
- Dividend yield of 1.78% provides steady income.
- Quarterly PAT growth of 21.3% shows earnings momentum.
- Low debt-to-equity (0.02) ensures financial resilience.
Limitation
- High P/E (40.2) compared to industry average (30.9).
- Negative PEG ratio (-2.03) indicates poor growth valuation.
- Stock trading below DMA levels, showing bearish trend.
- Decline in both FII (-0.01%) and DII (-0.02%) holdings.
Company Negative News
- No major negative news reported, but valuation and growth concerns persist.
Company Positive News
- Strong quarterly profit growth (+21.3%).
- Operational efficiency reflected in high ROCE and ROE.
Industry
- Pharmaceutical sector remains resilient with long-term demand drivers.
- Industry P/E of 30.9 reflects optimism in healthcare stocks.
Conclusion
✅ Glaxo is a financially strong company with excellent profitability and moderate dividend yield. However, high valuations and a negative PEG ratio limit its attractiveness for long-term growth investors. Ideal entry is near ₹2,200–₹2,300. Existing investors should hold cautiously for 2–3 years, with partial profit booking near ₹3,200–₹3,400 resistance levels.